Evidence map›Paper›PMID 34125596›Full record

ArticleAntimicrobial agents and chemotherapy2021

Efficacy of Omadacycline against Multidrug-Resistant Enterococcus faecium Strains in a Mouse Peritonitis Model.

Kavindra V Singh, Cesar A Arias, Barbara E Murray

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Kavindra V SinghDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Cesar A AriasDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Barbara E MurrayDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
The University of Texas Health Science Center at Houston · USUniversidad El Bosque · CO

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2025
$12.0M
VENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9M
The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7M
A Pharmacologic Approach to Prevent Daptomycin Resistance in VRER01AI121400 · NIAID · WAYNE STATE UNIVERSITY · PI RYBAK, MICHAEL JOSEPH · 2016 to 2020
$1.9M
Molecular Mechanisms Of Daptomycin Resistance In EnterococciR01AI093749 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2011 to 2015
$1.9M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
Texas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3M
Enterococcus faecium virulence: A molecular and therapeutic approachR00AI072961 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2009 to 2010
$593k
Molecular basis of the cefazolin inoculum effectR21AI143229 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2019 to 2020
$442k
Developing a better understanding of expression and function of PBP5-R of Enterococcus faecium for future development of therapeutic modalities for VRE infectionsR21AI133289 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MURRAY, BARBARA E · 2018 to 2019
$439k
HHS | National Institutes of Health (NIH) R21AI133289-01A1NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R00 AI072961NIAID NIH HHS R01 AI093749NIAID NIH HHS R01 AI121400NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS R21 AI133289NIAID NIH HHS R21 AI143229NIAID NIH HHS T32 AI141349NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

Omadacycline (OMC) showed better

Indexed as

Enterococcus faeciumGram-Positive Bacterial InfectionsPeritonitisAnimalsAnti-Bacterial AgentsMiceMicrobial Sensitivity TestsTetracyclinesAnti-Bacterial AgentsomadacyclineTetracyclinesE. faeciummouse peritonitisomadacycline

Identifiers

PMID34125596
PMCPMC8370196
OpenAlexW3172163111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.